Pharmafile Logo
Pharmafocus logo
Advanced Search

Bristol-Myers Sqibb

Showing 3 posts of 3 posts found.

Scottish regulators back BMS’ Opdivo for lung cancer

July 13, 2016
Research and Development, Sales and Marketing Bristol-Myers Sqibb, NICE, Scottish Medicines Consortium, lung cancer, opdivo, regulation

Bristol-Myers Squibb (NYSE: BMY) said the Scottish Medicines Consortium (SMC) has recommended cancer immunotherapy Opdivo (nivolumab) to treat advanced squamous …

News
bms

BMS criticises Scottish regulator over Opdivo skin cancer ‘no’

March 7, 2016
Medical Communications, Research and Development Bristol-Myers Sqibb, NICE, SMC, melanoma, opdivo

Bristol-Myers Squibb says the Scottish Medicines Consortium’s (SMC) decision not to recommend its immunotherapy Opdivo (nivolumab) as a monotherapy for …

News
rd_hands

Japan’s Ono Pharma focusing on building immuno-oncology portfolio with Opdivo

March 7, 2016
Sales and Marketing Bristol-Myers Sqibb, Ono Pharma, immuno-oncology, opdivo

Japan’s Ono Pharmaceutical has said it is focused on building on its immuno-oncology portfolio following the success of its PD-1 …

News

Latest content

AbbVie invests €150m in new R&D facility in Germany

May 3, 2024

AstraZeneca shares positive interim results from phase 3 lymphoma trial

May 3, 2024

Merck shares data from phase 3 trial of Keytruda for gastric cancers

May 2, 2024

Verona Pharma to share phase 3 COPD trial data at ATS 2024

May 2, 2024

Beckman Coulter Life Sciences and Watchmaker Genomics enter collaboration

May 1, 2024